Related Experiment Videos

Severe community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in a 6-year-old boy

David C Lung1, Y H Chan, L Kwong

  • 1Department of Clinical Pathology, Tuen Mun Hospital, Tuen Mun, Hong Kong. h9910303@yahoo.com.hk

Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|October 8, 2011
PubMed

Insights

Macrolide-resistant Mycoplasma pneumoniae causes severe pneumonia in children. This study found 33% of pediatric pneumonia cases resistant to macrolides, indicating a growing public health concern.

Area of Science:

  • Pediatric Infectious Diseases
  • Microbiology
  • Antimicrobial Resistance

Background:

  • Mycoplasma pneumoniae is a primary cause of atypical pneumonia in children.
  • Macrolide antibiotics are standard treatment for community-acquired pneumonia unresponsive to beta-lactams.
  • Emergence of antibiotic resistance is a significant global health challenge.

Observation:

  • A case of severe community-acquired pneumonia in a child caused by macrolide-resistant Mycoplasma pneumoniae is reported.
  • The resistant strain exhibited an A-to-G transition at position 2063 of the 23s rRNA gene.
  • Two additional macrolide-resistant M. pneumoniae strains were identified among 10 pediatric chest infection cases.

Findings:

  • Macrolide-resistant Mycoplasma pneumoniae accounted for 33% (3 out of 10) of polymerase chain reaction-confirmed cases.
  • The specific genetic mutation (A2063G) in the 23s rRNA gene was identified in the resistant isolates.
  • This highlights a concerning prevalence of macrolide resistance in pediatric M. pneumoniae infections.

Implications:

  • Urgent need for updated treatment guidelines for pediatric pneumonia.
  • Importance of molecular surveillance for tracking antimicrobial resistance patterns.
  • Potential for macrolide resistance to complicate the management of pediatric respiratory infections.

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: